Evidence map›Paper›PMID 39696618›Full record

ArticleEuropean journal of medical research2024

Cross-talk between cuproptosis and ferroptosis to identify immune landscape in cervical cancer for mRNA vaccines development.

Xuchao Zhang, Wenwen Xu, Zi Wang, Jing Liu, Han Gong, Wen Zou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuchao Zhang *Department of Oncology, The Second Xiangya Hospital, Central South University, No. 72 Xiangya Road, Changsha, 410000, Hunan, China.
Wenwen Xu *Department of Oncology, The Second Xiangya Hospital, Central South University, No. 72 Xiangya Road, Changsha, 410000, Hunan, China.
Zi WangDepartment of HematologyMolecular Biology Research Center, Center for Medical Genetics, School of Life SciencesHunan Province Key Laboratory of Basic and Applied Hematology, The Second Xiangya Hospital of Central South University, Central South University, No. 72 Xiangya Road, Changsha, 410011, China.
Jing LiuDepartment of HematologyMolecular Biology Research Center, Center for Medical Genetics, School of Life SciencesHunan Province Key Laboratory of Basic and Applied Hematology, The Second Xiangya Hospital of Central South University, Central South University, No. 72 Xiangya Road, Changsha, 410011, China.
Han GongDepartment of Oncology, The Second Xiangya Hospital, Central South University, No. 72 Xiangya Road, Changsha, 410000, Hunan, China. hangong@csu.edu.cn.
Wen ZouDepartment of Oncology, The Second Xiangya Hospital, Central South University, No. 72 Xiangya Road, Changsha, 410000, Hunan, China. zouwen29w@csu.edu.cn.

Funding

Postgraduate Scientific Research Innovation Project of Hunan Province CX20220132
6 · The paper itself

Abstract

Messenger RNA (mRNA)-based vaccines present a promising avenue for cancer immunotherapy; however, their application in cervical cancer remains unexplored. This study investigated the interplay between the regulated cell death pathways of cuproptosis and ferroptosis to advance the development of mRNA vaccines for cervical cancer. We identified key cuproptosis-related and ferroptosis-related genes (CFRGs) from public mRNA profiles and determined their prognostic significance, mutation frequencies, and effect on the immune landscape. Our analysis revealed two distinct subtypes of cervical cancer associated with CFRGs, with differences in prognosis and immune characteristics. Using LASSO, XGBoost, and SVM-RFE methods, we established a 4-gene prognostic signature (TSC22D3, SQLE, ZNF419, and TFRC) to stratify patients based on their risk and determine its correlation with immune microenvironment, mutation profiles, and treatment responses. RT-qPCR validation confirmed the differential expression of these genes in clinical samples. Our findings identify TSC22D3, SQLE, ZNF419, and TFRC as candidate targets for mRNA vaccine development and offer a potential prognostic tool for personalized cervical cancer treatment.

Indexed as

FerroptosisUterine Cervical NeoplasmsCancer VaccinesFemaleGene Expression Regulation, NeoplasticHumansmRNA VaccinesPrognosisRNA, MessengerTumor MicroenvironmentVaccine DevelopmentCancer VaccinesmRNA VaccinesRNA, MessengerCervical cancerCuproptosisFerroptosisImmunotherapyMRNA vaccinesPrognosis

Identifiers

PMID39696618
PMCPMC11657287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.